American Bio Medica Corporation
Other OTCTotal Valuation
American Bio Medica Corporation carries a market capitalization of 4,810.00, placing it among publicly traded companies globally. Its enterprise value stands at 954,735.64, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4,810.00 |
| Enterprise Value | 954,735.64 |
Share Statistics
American Bio Medica Corporation currently has 48.10M shares outstanding.
| Shares Outstanding | 48.10M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
American Bio Medica Corporation trades at a trailing price-to-earnings ratio of 1.00. The price-to-sales ratio is 1.17, and the price-to-book ratio stands at -0.04.
| PE Ratio | 1.00 |
| PS Ratio | 1.17 |
| PB Ratio | -0.04 |
| P/TBV Ratio | -1.85 |
| P/FCF Ratio | -0.76 |
| P/OCF Ratio | -0.76 |
Enterprise Valuation
| EV / Sales | 1.32 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 135.09 |
Financial Position
American Bio Medica Corporation maintains a current ratio of 0.59, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -38.21, indicating conservative leverage, while an interest coverage ratio of -6.45 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.59 |
| Quick Ratio | 0.32 |
| Debt / Equity | -38.21 |
| Debt / EBITDA | -0.16 |
| Interest Coverage | -6.45 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 76.44 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -4.53 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.17 |
Taxes
Over the trailing twelve months, American Bio Medica Corporation has paid 2,000.00 in income taxes, reflecting an effective tax rate of 0.23.
| Income Tax | 2,000.00 |
| Effective Tax Rate | 0.23 |
Income Statement
Over the trailing twelve months, American Bio Medica Corporation generated 725,000.00 in revenue and converted that into 850,000.00 in net income, yielding earnings per share of 0.02. EBITDA reached -1.08M, while operating income came in at -1.12M.
| Revenue | 725,000.00 |
| Gross Profit | -58,000.00 |
| Operating Income | -1.12M |
| Pretax Income | 852,000.00 |
| Net Income | 850,000.00 |
| EBITDA | -1.08M |
| EBIT | -1.12M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
American Bio Medica Corporation holds 68,000.00 in cash and equivalents against 175,000.00 in total debt, resulting in a net debt position of 107,000.00. Total book value stands at -22.86M, with working capital of -458,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 68,000.00 |
| Total Debt | 175,000.00 |
| Net Debt | 107,000.00 |
| Equity (Book Value) | -22.86M |
| Book Value Per Share | -0.48 |
| Working Capital | -458,000.00 |
Cash Flow
American Bio Medica Corporation produced -1.12M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.12M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.12M |
| FCF Per Share | -0.02 |
Margins
American Bio Medica Corporation operates with a gross margin of -20.41, reflecting its pricing power and cost economics. The operating margin of -154.90 and net profit margin of 117.24 provide insight into operational efficiency.
| Gross Margin | -20.41 |
| Operating Margin | -154.90 |
| Pretax Margin | 117.52 |
| Profit Margin | 117.24 |
| EBITDA Margin | -148.55 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -108.76 |
| FCF Yield | -131.88 |
Scores
American Bio Medica Corporation posts an Altman Z-Score of -54.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -54.49 |